NVO
NYSE · Healthcare
Novo Nordisk A/S
$38.58
+0.62 (+1.63%)
Financial Highlights (FY 2026)
Revenue
1.90T
Net Income
631.10B
Gross Margin
81.0%
Profit Margin
33.1%
Rev Growth
+20.4%
D/E Ratio
0.67
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | |
|---|---|---|
| Gross Margin | 81.0% | 81.0% |
| Operating Margin | 41.3% | 37.2% |
| Profit Margin | 33.1% | 31.5% |
Income Statement
| FY 2026 | FY 2025 | |
|---|---|---|
| Revenue | 1.90T | 1.58T |
| Gross Profit | 1.54T | 1.28T |
| Operating Income | 786.42B | 587.71B |
| Net Income | 631.10B | 471.64B |
| Gross Margin | 81.0% | 81.0% |
| Operating Margin | 41.3% | 37.2% |
| Profit Margin | 33.1% | 31.5% |
| Rev Growth | +20.4% | +20.4% |
Balance Sheet
| FY 2026 | FY 2025 | |
|---|---|---|
| Total Debt | 213.00B | 213.00B |
| Total Equity | 315.61B | 315.61B |
| D/E Ratio | 0.67 | 0.67 |
Cash Flow
| FY 2026 | FY 2025 | |
|---|---|---|
| EBITDA | 921.94B | 727.26B |
| Free Cash Flow | — | — |